$FEMY

Sipos Jeremy Alexander purchased $10K of FEMY

Sipos Jeremy Alexander (Chief Technology Officer) purchased 3,125 shares of FEMASYS INC (FEMY) at $3.20 on 2026-08-07.

Original reporting
SEC EDGAR · Sipos Jeremy Alexander
Published Aug 12, 2026, 12:44 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 1:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FEMY
Bullish
low confidence
Mentioned
$FEMY
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FEMYBullishLow
01

Why it matters

The only new information is the CTO’s $10,000 open-market purchase; it does not include guidance, contracts, litigation, or operational updates.

02

Market read

Traders may note the insider buy as a small sentiment input, but there is no fundamental news to reprice the stock materially.

03

What to watch

The filing does not state motivations, and the absence of a 10b5-1 plan does not by itself confirm conviction or timing advantage.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-11, transaction dated 2026-08-07

Background

The article is an SEC Form 4 insider transaction disclosure for FEMASYS Inc.

Company-level read

Ticker impact

$FEMYBullishLow confidence
Context

FEMASYS CTO Sipos Jeremy Alexander bought 3,125 shares at $3.20 on 2026-08-07, totaling $10,000, per Form 4.

Expected impact

Limited, likely sentiment-only effect; no clear directional catalyst beyond insider signaling.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with relatively small dollar value and no accompanying company-specific operational or financial update.

Market effects

No sector-level implications disclosed; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider buys can be discretionary and may reflect diversification or compensation timing rather than a strong forward view.

Key entities

  • FEMASYS INC

    Company whose insider transaction was reported on Form 4.

  • Sipos Jeremy Alexander

    Chief Technology Officer who purchased shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$JNJMedAI 8/10

Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials

Johnson & Johnson (JNJ) received CE Marking for ACUVUE OASYS MAX 2-Week contact lenses. GSK (GSK) expanded Shingrix approval in Japan. Axogen (AXGN) to acquire BioCircuit for $200M. Femasys (FEMY) partnered with CapexMD for fertility financing. EpilepsyGTx collaborated with Viralgen (BAYN.DE) for gene therapy. HCW Biologics (HCWB) partnered with Akron Biotech. Bluejay Diagnostics (BJDX) teamed with Lovell for federal market access. Transgene (TNG.PA) expanded partnership with ProBioGen. Oncolyti

$GILDMedAI 8/10

Weekly Buzz: Gilead Sciences, Roivant Sciences Win FDA Nod; Biohaven, Eli Lilly Strike Deal; Spyre Therapeutics Misses Monotherapy Goal

Gilead (GILD) and Roivant (ROIV) received FDA approvals for Bixlenvo and LISRAYA, respectively. Johnson & Johnson (JNJ) also gained approval for IMAAVY. Biohaven (BHVN) and Eli Lilly (LLY) advanced partnerships. Spyre Therapeutics missed a clinical trial goal. Key stocks: GILD +0.52%, ROIV +2.26%, JNJ -1.57%.

$FEMYMed

FEMASYS INC (FEMY): Results of Operations and Financial Condition

FEMASYS INC (FEMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update -- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed ® fertility portfolio and advancement of the FemBloc ® clinical and regulatory pr

$FEMYMedAI 8/10

Femasys Stock Falls 11% Over Announcement Of $30 Mln Private Placement

Femasys Inc. (FEMY) shares fell 11.07% to $2.65 after the company announced a $30 million private placement on Nasdaq. Femasys will sell 9.37 million shares plus pre-funded warrants and warrants for 18.75 million shares, priced at $3.20. Lead investor is Nantahala Capital, with others including Rosalind Advisors. Potential extra cash proceeds up to $60 million if warrants are exercised.

$FEMYMedAI 8/10

Femasys Inc.: Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

Femasys Inc. (NASDAQ: FEMY) said it entered a $30 million private placement with accredited investors led by Nantahala Capital, with participation from other healthcare funds and management. It will sell 9,374,999 shares plus pre-funded and accompanying warrants. If all warrants are exercised, Femasys could receive up to $60 million more. Closing is expected around Aug. 10, 2026.